Quest Diagnostics shares reached a new 52-week high of $216.87, gaining 11.5% over the past month and 24.5% year-to-date. The company reported first-quarter earnings of $2.50 per share, surpassing the consensus estimate of $2.37, and beat revenue expectations by 3.14%. For the current fiscal year, analysts project earnings of $10.72 per share on $11.84 billion in revenues, representing 8.83% EPS growth. The stock carries a Zacks Rank of 2, or Buy, supported by positive earnings estimate revisions, and a VGM Score of B. Industry peer Aveanna Healthcare Holdings also holds a Zacks Rank of 2 and has seen its shares rise 30.7% over the past month.
Quest Diagnostics IncorporatedBeat earnings and revenue estimates, driving stock to 52-week high.
Aveanna Healthcare Holdings Inc